Evaxion expands its preclinical bacterial vaccine portfolio in collaboration with a leading pharmaceutical company
Wednesday, September 20, 2023
Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of immunotherapies based on on AI, today announced the launch of a new research program, EVX-B3, an AI-engineered vaccine candidate against an undisclosed bacterial pathogen. The new vaccine project is part of a collaboration between Evaxion and an undisclosed leading pharmaceutical company leveraging the unique assets and know-how of both organizations.
To develop an effective vaccine, Evaxion has launched identification activities for EVX-B3 using its two AI platforms EDEN™ and RAVEN™ to identify protective antigens capable of eliciting both a humoral response (antibody ) and cellular to the pathogen. EVX-B3 aims to solve a serious global medical problem, by targeting a pathogen associated with repeated infections, increasing incidence as well as often serious medical complications, and for which no vaccine is currently available. This project is part of a collaborative effort that will be co-financed by the two companies.
Birgitte Rønø, Scientific Director of Evaxion, said: “We are delighted to announce our next collaboration which aims to jointly study the capabilities of our AI platforms with the aim of designing a breakthrough vaccine targeting this specific pathogen. We are confident that this collaboration will further validate the power of AI to benefit global health through the design of unique vaccines against serious diseases.
About EVAXION
Evaxion Biotech A/S is a clinical-stage biotechnology company developing cutting-edge AI platforms. Evaxion's proprietary and scalable technologies harness the power of artificial intelligence to decode the human immune system and develop new immunotherapies against cancer, bacterial diseases and viral infections. The company is committed to transforming the lives of patients with unmet clinical needs by providing innovative and targeted treatment options.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target”, “believe”, “expect”, “hope”, “aim”, “intend”, “may”, “could”, “anticipate”, “consider”, “continue” ", "estimate", "plan", "potential", "predict", "project", "will", "may have", "likely", "should" and other words or terms of similar meaning characterize the forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements due to various factors, including, but not limited to, risks related to: our financial condition and our needs for additional capital; our development work; the cost and success of our product development and preclinical and clinical testing activities; the commercialization of any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties, including for the conduct of clinical trials and manufacturing of products; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee issues and growth management; our ADSs and ordinary shares; the impact of international factors on the economic level, political, legal, regulatory, social and commercial, including inflation, and the effects on our business of the global COVID-19 pandemic and the ongoing conflict in the region surrounding Ukraine and Russia; and other uncertainties affecting our business operations and financial condition. For a more in-depth discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at the address and the effects on our business of the global COVID-19 pandemic and the ongoing conflict in the region surrounding Ukraine and Russia; and other uncertainties affecting our business operations and financial condition. For a more in-depth discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at the address and the effects on our business of the global COVID-19 pandemic and the ongoing conflict in the region surrounding Ukraine and Russia; and other uncertainties affecting our business operations and financial condition.
